“When a patient is suffering from ADHF, the amount of blood the heart pumps to the kidneys may be insufficient for the kidneys to work at full capacity,” Gillian Grafton, DO, co-principal investigator on the trial at Henry Ford, said in a June 3 news release. “The kidneys are responsible for maintaining the fluid balance that keeps heart failure congestion in check. Heart failure by itself is a chronic and progressive condition, but the additional complication of reduced kidney function can significantly worsen a patient’s condition.”
The heart pump, smaller than the size of a No. 2 pencil, is implanted using a catheter and is meant to relieve some of the heart’s stress, allowing the organ to recover while improving blood flow to the kidneys. The intra-aortic axial flow pump, made by Procyrion, is being investigated as part of a clinical trial in the U.S. and Australia, with Henry Ford being the only U.S. site involved in the trial.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
